Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
C4x Discovery Holdings Plc LSE:C4XD London Ordinary Share GB00BQQ2RV18 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 18.00 17.00 19.00 18.00 18.00 18.00 77,303 07:41:12
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -13.6 -18.8 - 21

C4X Discovery Holdings PLC Clive Dix appointed to the UK Vaccine Taskforce

05/06/2020 7:00am

UK Regulatory (RNS & others)


C4x Discovery (LSE:C4XD)
Historical Stock Chart


From Mar 2020 to Sep 2020

Click Here for more C4x Discovery Charts.

TIDMC4XD

RNS Number : 0418P

C4X Discovery Holdings PLC

05 June 2020

C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company")

Clive Dix appointed to the UK Vaccine Taskforce

Government's taskforce to lead UK efforts to deliver a COVID-19 vaccine

5 June 2020 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, is pleased to confirm that Clive Dix, Chief Executive Officer of C4XD has been appointed a member and Deputy Chair of the Steering Board of the UK Vaccine Taskforce, the group set up by the Government's Chief Scientific Adviser, Deputy Chief Medical Officer, Business Secretary and Health Secretary to lead UK efforts to find and manufacture a COVID-19 vaccine.

Clive remains committed to delivering C4XD's strategy and this appointment will not impact his day-to-day role as CEO.

Eva-Lotta Allan, Chairman of C4XD, commented:

"We are very proud that Clive has been appointed to this important and prestigious taskforce. COVID-19 has had such a devastating impact not only in the UK, but across the world. The development of a vaccine is vital to saving lives and enabling everyone to get back to normality. The taskforce has been assembled to bring together the brightest minds in the scientific industry to deliver a COVID-19 vaccine that will be effective and accessible. Clive's rich and diverse experience, both as a scientist and from managing pharmaceutical companies, means he understands what is required to bring a product like this to market. This will be invaluable to the taskforce as it works quickly to find a solution to the COVID-19 pandemic."

- Ends -

Contacts

 
 C4X Discovery Holdings 
 Mo Noonan, Communications                    +44 (0)787 6444977 
 
 Panmure Gordon (UK) Limited (NOMAD and 
  Broker) 
 Freddy Crossley, Emma Earl (Corporate 
  Finance)                                    +44 (0)20 7886 2500 
 James Stearns (Corporate Broking) 
 
 C4X Discovery Media - Consilium Strategic 
  Communications 
 Mary-Jane Elliott, Chris Gardner, Matthew 
  Neal                                        +44 (0)203 709 5700 
 

Notes to Editors:

About the UK Vaccine Taskforce

The Taskforce is supporting efforts to develop a COVID-19 vaccine as soon as possible by providing industry and research institutions with the resources and support needed. This includes working with regulators and scaling up manufacturing, so that when a vaccine is identified, it can be produced quickly and at scale.

The Bioindustry Association is working closely with the Taskforce, bringing together a whole range of businesses keen to use their expertise to mass-produce vaccines, as soon as one is ready.

About C4X Discovery

C4X Discovery (C4XD) aims to create the world's most productive Drug Discovery engine by using cutting-edge technologies and expertise to efficiently deliver best-in-class small-molecule medicines to clinical partners for the benefit of patients. The Company's business model focuses on replenishing big pharma discovery pipelines and driving returns through revenue generating pre-clinical licensing deals. In 2018, C4XD successfully out-licensed a pre-clinical programme in addictive disorders to Indivior in a deal worth up to $294m.

C4XD has a state-of-the-art suite of proprietary technologies across the Drug Discovery process and accesses further innovative capabilities and expertise through its growing network of partners. The Company is actively advancing its diverse pre-clinical discovery portfolio which is focused on inflammation, neurodegeneration and oncology (including immuno-oncology). Opportunities to maximise value from the portfolio are proactively driven by C4XD's commercial division. The Company is led by a highly experienced management team and Board who have delivered significant value creation within the healthcare sector.

For additional information please go to: www.c4xdiscovery.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCFIMMTMTBMTJM

(END) Dow Jones Newswires

June 05, 2020 02:00 ET (06:00 GMT)

1 Year C4x Discovery Chart

1 Year C4x Discovery Chart

1 Month C4x Discovery Chart

1 Month C4x Discovery Chart
ADVFN Advertorial
Your Recent History
LSE
C4XD
C4x Discov..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20200926 21:26:47